VANCOUVER – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid cannabinol (“CBN”) as the active pharmaceutical ingredient (“API”) in its two product candidates under development: INM-755 for epidermolysis bullosa (“EB”) and INM-088 for glaucoma. InMed is leading the way in the clinical development of CBN to treat human disease.
“We are proud to be the first company to investigate cannabinol’s therapeutic potential in human clinical trials,” commented InMed CEO, Eric A. Adams. “InMed has completed more than 30 preclinical pharmacology and toxicology studies, identifying potential therapeutic advantages of CBN in specific disease models over the more common cannabinoids THC and CBD, as well as other rare variants.” Mr. Adams continued, “We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need.”
InMed’s scientific team today officially revealed CBN as the API in INM-755 at the EB2020 World Congress in London, UK, where they will also exhibit preclinical data in support of the INM-755 program in EB.
INM-755 is being developed as InMed’s lead dermatological product candidate for the treatment of symptoms related to EB, a rare genetic skin disease characterized by fragile skin that can lead to extensive wounds and blistering. INM-755 is formulated as a CBN-based topical cream. In addition to relief of symptoms, including inflammation and pain, InMed believes INM-755 may enhance skin integrity in a subset of EB Simplex patients. Following regulatory and ethics committee approval in December 2019, InMed initiated a Phase 1 clinical trial for INM-755 in healthy volunteers.
CBN is also the API in InMed’s second product candidate, INM-088, being investigated as a potential treatment for ocular disease. INM-088 is in preclinical testing and advanced formulation development with an aim to decrease intraocular pressure and provide neuroprotection for individuals suffering from glaucoma.
Both INM-755 and INM-088 are designed for topical administration at the disease site, seeking to avoid potential side effects related to systemic exposure. InMed has filed patents to protect its use of CBN and other rare cannabinoids to treat these and other potential diseases, as well as patents directed towards our proprietary biosynthesis platform.
About InMed
InMed Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of cannabinoid-based medications that target diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com
